Accordingly, there is a high clinical relevance of testing brain tumors for the presence of BRAF mutations/fusions as targeted therapies for BRAF aberrations are available with the clinical introduction for metastatic malignant melanoma [5]. This evidence concerns the gene BRAF and metastatic melanoma.